Acadia drug awarded

has been awarded a grant from the Michael J. Fox Foundation for the development of a novel estrogen receptor beta agonists for the treatment of Parkinson's disease. The Michael J. Fox Foundation was Founded in 2000, dedicated to ensuring the development of a cure for Parkinson's disease within the coming decade through an aggressively funded research agenda.

managed by Roger Olsson at the Malmö based research center of Acadia Pharmaceutical. The grant of up to USD 830 000 was awarded under the Foundation's Therapeutics Development Initiative. It aimed at supporting preclinical development of Parkinson's disease therapies that have the potential for fundamentally altering disease course and improving treatment of symptoms above and beyond current standards of care.

technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. The company's researchers have identified novel and selective estrogen receptor beta agonists that may address the motor and non-motor symptoms of Parkinson's disease. The company’s researchers will examine the efficacy of the estrogen receptor beta agonists in preclinical models, focusing on neuroprotection, motor performance, cognition and sensorimotor gating.